CN1347320A - 降胆固醇剂的应用 - Google Patents

降胆固醇剂的应用 Download PDF

Info

Publication number
CN1347320A
CN1347320A CN00803519A CN00803519A CN1347320A CN 1347320 A CN1347320 A CN 1347320A CN 00803519 A CN00803519 A CN 00803519A CN 00803519 A CN00803519 A CN 00803519A CN 1347320 A CN1347320 A CN 1347320A
Authority
CN
China
Prior art keywords
levels
pharmaceutically acceptable
compound
ldl
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00803519A
Other languages
English (en)
Chinese (zh)
Inventor
A·拉扎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1347320(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902590.0A external-priority patent/GB9902590D0/en
Priority claimed from GBGB9921062.7A external-priority patent/GB9921062D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1347320A publication Critical patent/CN1347320A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN00803519A 1999-02-06 2000-02-01 降胆固醇剂的应用 Pending CN1347320A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9902590.0A GB9902590D0 (en) 1999-02-06 1999-02-06 Use of cholesterol-lowering agent
GB9902590.0 1999-02-06
GBGB9921062.7A GB9921062D0 (en) 1999-09-08 1999-09-08 Use of cholestrol-lowering agent
GB9921062.7 1999-09-08

Publications (1)

Publication Number Publication Date
CN1347320A true CN1347320A (zh) 2002-05-01

Family

ID=26315084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00803519A Pending CN1347320A (zh) 1999-02-06 2000-02-01 降胆固醇剂的应用

Country Status (22)

Country Link
EP (1) EP1150679A1 (https=)
JP (2) JP2002536333A (https=)
KR (1) KR100699287B1 (https=)
CN (1) CN1347320A (https=)
AR (1) AR022462A1 (https=)
AU (1) AU769897B2 (https=)
BR (1) BR0007991A (https=)
CA (1) CA2358641A1 (https=)
CZ (1) CZ20012631A3 (https=)
EE (1) EE04659B1 (https=)
HK (1) HK1040924A1 (https=)
HU (1) HUP0105019A3 (https=)
ID (1) ID30131A (https=)
IL (1) IL144662A0 (https=)
IS (1) IS5996A (https=)
MY (1) MY136382A (https=)
NO (1) NO319827B1 (https=)
NZ (1) NZ512681A (https=)
PL (1) PL349137A1 (https=)
SK (1) SK11112001A3 (https=)
TR (1) TR200102236T2 (https=)
WO (1) WO2000045819A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
SE0103509D0 (sv) * 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2007142581A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Combination product for the treatment or prevention of dyslipidaemia
CA2689523A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
EP2166847B1 (en) 2007-06-20 2014-11-19 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
WO2008156715A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Cetp inhibitors derived from benzoxazole arylamides
EP2216095A1 (en) * 2009-01-27 2010-08-11 Koninklijke Philips Electronics N.V. Microfluidic device for full blood count

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260446A (en) * 1989-12-22 1993-11-09 Basf Aktiengesellschaft Aminothiazoles
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体

Also Published As

Publication number Publication date
KR20010089631A (ko) 2001-10-06
AR022462A1 (es) 2002-09-04
AU2305100A (en) 2000-08-25
NO20013810D0 (no) 2001-08-03
MY136382A (en) 2008-09-30
NO20013810L (no) 2001-10-03
EE200100404A (et) 2002-10-15
ID30131A (id) 2001-11-08
HUP0105019A2 (hu) 2002-05-29
WO2000045819A1 (en) 2000-08-10
KR100699287B1 (ko) 2007-03-26
IL144662A0 (en) 2002-05-23
CA2358641A1 (en) 2000-08-10
NZ512681A (en) 2003-12-19
AU769897B2 (en) 2004-02-05
JP2011137023A (ja) 2011-07-14
HUP0105019A3 (en) 2003-02-28
HK1040924A1 (zh) 2002-06-28
EE04659B1 (et) 2006-08-15
SK11112001A3 (sk) 2002-02-05
TR200102236T2 (tr) 2001-12-21
BR0007991A (pt) 2001-11-06
CZ20012631A3 (cs) 2001-10-17
JP2002536333A (ja) 2002-10-29
EP1150679A1 (en) 2001-11-07
PL349137A1 (en) 2002-07-01
NO319827B1 (no) 2005-09-19
IS5996A (is) 2001-07-10

Similar Documents

Publication Publication Date Title
US6369103B1 (en) Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US6982157B1 (en) Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s) -3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3A4
US20120014907A1 (en) Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
JP2011137023A (ja) コレステロール低下薬の使用
Golper et al. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria
US20190209555A1 (en) Ketoconazole enantiomer in humans
Thompson et al. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study
Hagemenas et al. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia
Hussar New drugs of 2003
TW200808313A (en) Compositions and methods for treating rheumatoid arthritis
US20220370446A1 (en) Methods For Reducing Liver Fat and For Treating Fatty Liver Disorders
Di Giambenedetto et al. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure
Patnaik et al. First-in-human Phase 1 study of BTX-9341, a first-in-class, CDK4/6 bifunctional degrader, as a monotherapy and in combination with fulvestrant in patients with advanced and/or metastatic HR+/HER2-breast cancer
MXPA01007294A (es) Uso de un agente que reduce colesterol
WO2023109825A1 (zh) 氧化银和/或其水合物在制备药物中的用途
WO2023109826A1 (zh) 碳酸银在制备药物中的用途
US20250295662A1 (en) Use of cdk4/6 inhibitor in treatment of dedifferentiated liposarcoma
WO2022246243A1 (en) Methods of defining functional change and slowing progression in chronic liver disease
RU2023132992A (ru) Способы выявления пациентов с онкологическими заболеваниями для комбинированного лечения
TW202604485A (zh) 患有肝損傷患者肝疾病之治療
Jancin Bone Hormone May Predict Mortality in HF
HU226062B1 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
WO2005107746A1 (ja) 脂質代謝異常の予防または治療用医薬組成物
Thompson A Case Of Xanthomatous Neuropathy
Mahoney Organization and Development of a Computerized Drug-Drug Interaction File

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication